If you’re choosing between Trelegy and Symbicort, cost matters. Trelegy is a newer triple-combination inhaler (steroid + LAMA + LABA). Symbicort is a long-established steroid + LABA inhaler. That extra medication in Trelegy usually means a higher price tag. Below I break down why prices differ and simple ways to pay less.
First, Trelegy is branded triple therapy. Newer, patent-protected drugs tend to be pricier. Symbicort has been on the market longer and there are more price options — sometimes generics or alternative combos are available depending on your country. Insurance also drives price: Trelegy may sit on a higher formulary tier and require prior authorization. Out-of-pocket costs depend on your plan, whether you hit a deductible, and whether your insurer prefers one drug over the other.
Other real cost drivers:
Exact prices change fast, but here’s a practical picture: branded Trelegy usually costs more per month than Symbicort. Without insurance, many people see Trelegy billed at several hundred dollars a month, while Symbicort or its generic alternatives often run lower. With good insurance or coupons, either can drop into a much lower range — sometimes under $100 per month.
Smart steps to lower your cost:
Want a quick next step? Call your insurer’s pharmacy line and ask: "What’s my copay for Trelegy vs Symbicort, and is prior authorization required?" That single call often clears up the biggest unknown and points you to the cheapest, safe option for your treatment.
A hands-on breakdown of Trelegy vs Symbicort—costs, patient satisfaction, and which inhaler offers real value for those with asthma or COPD in 2025.
full article